AZTR executed another reverse stock split (1-for-6.66 in August 2025) while burning through over half its cash reserves and increasing net losses by 22%.
The third stock split in two years (following previous reverse splits) combined with accelerating losses and declining cash position suggests severe financial distress for this early-stage biotech. While the company reported initial Phase 1b safety results in 2025, the deteriorating financial metrics indicate potential funding challenges ahead.
AZTR's financial position weakened significantly with cash declining 55% to just $2.1M while net losses increased 22% to $11M, creating a concerning cash burn trajectory. Total assets fell 32% and current assets dropped 42%, though stockholders' equity surprisingly improved 73% and liabilities decreased 26%, likely due to the reverse stock split accounting treatment. The combination of accelerating losses, declining cash reserves, and the need for another reverse stock split signals potential liquidity constraints for this clinical-stage biopharmaceutical company.
Receivables surged 291.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Capital expenditure jumped 182.6% — major investment cycle underway; assess returns on deployment.
Equity base grew 72.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash declined 54.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 42.3% — monitor working capital adequacy and short-term liquidity.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Total assets contracted 31.7% — asset sales, write-downs, or balance sheet optimization underway.
Liabilities reduced 26.3% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Net income declined 22.2% — review whether driven by operations, interest costs, or non-recurring items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →